

**Open Access** 

## Market analysis - 5th Annual Meet on Structural Biology

### August 24-25, 2020 Dublin,Ireland

#### Dr. Emochini Wax

Professor, Department of Biology, University of Ireland, E-mail: <u>chiniemo@outlook.com</u>

#### Market analysis:

The 5th Annual Meet on Structural Biology is slated to take place during August 24-25, 2020 at Dublin, Ireland which objects on foremost topics such as Structural biology, Systems Biology, Structural and Cell Biology, Bio-Engineering, Bio Physics and Structural Biology Immunology, Nano Engineering ,Stem cell biology and Regenerative medicine, Cancer Biology The past International conferences on **Cell** and Structural Biology strenuous on diverse areas related to Science and their extensive applications which have engaged protruding speakers which embraces eminent scientists from premium International Universities and experts from distinguished associations. Formerly organized conference can be seen in conference series webpage.

Biology market which earlier accounted for \$6.58 billion in 2019 is expected to reach \$8.78 billion by 2025, growing at a CAGR of 8.0% in the years 2019 and 2025. Europe holds the second largest share in the global microbiology market, including industrial, food and beverages, antibiotics and vaccines, or the automated technologies with many nations of the EU being strong competitors.

The growth of the clinical microbiology market for the hospitals and diagnostic centers segment is driven by the high incidence of target diseases (such as tuberculosis, HIV-AIDS, malaria, and epidemic diseases), availability of technologically advanced products (such as molecular diagnostic products, PCR and NGS-based instruments, and microscopy instruments) for infectious diseases diagnosis, growing awareness among doctors and clinicians regarding the advantages offered by molecular diagnostics products for fast and effective disease diagnosis, and on-going expansion of healthcare infrastructure across emerging countries.

The global clinical microbiology market size is projected to reach USD 5.3 billion by 2025 from USD 3.9 billion in 2020, at a CAGR of 6.5% during the forecast period. The global microbiological testing/clinical microbiology market offers significant growth potential for prominent as well as emerging product manufacturers. Technological advancements, rising incidence of infectious diseases and growing outbreak of epidemics (such as COVID-19), and increased funding and public-private investments are some of the key factors driving the growth of the microbiological testing/clinical microbiology market (**Figure1**).

## COVID-19 Impact on the global clinical microbiology market

The COVID-19 pandemic has significantly affected the clinical microbiology market. The market is facing challenges in the manufacturing and supply chain, such as delivering products to end-users in a timely manner as well as attending to an uneven demand for the products and services in the sector. In addition, a dearth of skilled lab professionals to conduct/study diagnostic tests, limited operations in most of the industries, inadequate funding for research and academic institutes, temporary closure of major academic institutes, disrupted supply chain, and challenges in providing essential/post-sales services due to lockdowns have led to the reduced supply of clinical microbiology products to end-users.

Research institutes are one of the major end-users of clinical microbiology products. As the pandemic resulted in the temporary closure of several research institutes across the globe, this end-user segment has been affected drastically over the last few months.

#### By product, the instruments segment is expected to have the largest market share during the forecast period

The large share of this segment is attributed to factors such as the significant adoption of conventional laboratory instruments among researchers and academia (coupled with growing industry-academia collaborations for genomic research), technological advancements in the field of molecular techniques and proteomics (such as the integration of microfluidics with PCR and nanotechnology with qPCR techniques), and the on-going trend of laboratory automation among clinical laboratories.

## Pharmaceuticals is the largest application segment of the clinical microbiology/microbial testing market.

The pharmaceutical applications segment is expected to dominate the overall microbial testing market during the forecast period. The large share of this segment is majorly attributed to the presence of well-established and globally accepted regulations that govern the evaluation of microbial contamination during pharmaceutical manufacturing and raw material sourcing.

Several regulatory bodies [such as the WHO, FDA, Medicines and Healthcare Products Regulatory Agency (MHRA, UK), European Medicines Evaluation Agency (European Union), Therapeutic Goods Administration (TGA, Australia), and the Brazilian Health Regulatory Agency (ANVISA, Brazil)] have well-defined regulatory guidelines for the evaluation of microbial contamination in excipients and APIs to ensure sterile manufacturing of drugs and microbial load testing of finished pharmaceutical products.

Additionally, pharmaceutical drug manufacturing processes are controlled and checked through various pharmacopeias globally. The growing volume of pharmaceutical drugs manufactured across the globe is another factor contributing to the growth of this application segment.

# Hospital & diagnostics centers accounted for the largest share of the clinical microbiology market, by end-users, in 2019

The growth of the clinical microbiology market for the hospitals and diagnostic centers segment is driven by the high incidence of target diseases (such as tuberculosis, HIV-AIDS, malaria, and epidemic diseases), availability of technologically advanced products (such as molecular diagnostic products, PCR and NGS-based instruments, and infectious diseases microscopy instruments) for diagnosis, growing awareness among doctors and clinicians regarding the advantages offered by molecular diagnostics products for fast and effective disease diagnosis, and ongoing expansion of healthcare infrastructure across emerging countries.

## North America is the largest regional market for Clinical Microbiology

North America (comprising the US and Canada) dominates the clinical microbiology market. North

America is a mature market, with high penetration of clinical microbiology technologies among key end-users (hospitals, diagnostic centers, research laboratories, and commercial service providers) and well-established distribution channels for clinical microbiology product manufacturers and suppliers.

Easy accessibility to and the high adoption of advanced diagnostic technologies due to the significant per capita annual healthcare expenditure by the US and Canadian governments, as well as supportive government regulations, are driving the growth of the clinical microbiology market in this region.

Ireland is a main worldwide contender for innovative work, while constantly achieving exact and enhanced mechanical headways in the field of research and turning out more intelligent innovative organizations over the globe. Ireland keeps on developing exponentially in the field of Molecular Diagnostics, Immunodiagnostics, Emerging tests and distinguishing proof and different other example screenings, applications and shrewd advances in recognizable proof. Ireland as of now has world's biggest and driving dairy and dairy items industry.

#### Societies in Europe:

• French Society of Theoretical Biology

- EMBL European Biology Institute
- European Society for Medical Oncology

•Hellenic Society for Computational Biology and Bioinformatics

• European Proteomics Association

•Israeli Society for Bioinformatics and Computational Biology

- Helmholtz Network for Bioinformatics
- Dutch Society for Theoretical Biology
- EM Bnet European Molecular Biology Network
- German Informatics Society
- Society for Bioinformatics in the Nordic Countries
- Czech Free and Open Bioinformatics Association




Figure 1: Biology market analysis.